|
The biomaterials company Artimplant, has received clearance for marketing in the USA for its rotator cuff reinforcement patch.
Arthrotek Inc., a Biomet company, will market the product under the name of Sportmesh™.
PA, US | Jan. 23, 2006 | The Rotator Cuff (RC) helps to lift and rotate the arm and to stabilize the shoulder. RC tear is a common cause of shoulder pain and disability. Currently more than 300,000 RC surgeries are performed each year in the USA. It is a condition seen both in the young and old. With age, the risk of RC injury increases since the muscle and tendon tissue of the RC looses some of its elasticity and becomes more susceptible to injuries. Causes of the injury may include every day activities such as lifting or reaching. The injury is also common among active people and people with physically demanding jobs.
The Artelon® based Sportmesh™ adds additional strength
In addition to using sutures or suture anchors for primary repair of RC tears, patients with extensive injury or poor tissue quality will benefit from additional support by applying the Artelon® RC reinforcement patch. The patch offers additional initial mechanical strength and provides a degradable scaffold that is incorporated into the patients own tissue. The long-term support from the degradable patch should increase long-term strength and minimize the risk of re-rupture. With the Artelon® RC reinforcement patch tissue irritation related to animal derived materials is eliminated.
Artelon® - a unique biomaterial
Sportmesh™ is made of Artelon®, a unique long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue - Artelon® offers new solutions to unmet clinical needs in several therapy areas.
For additional information, please contact:
Tord Lendau, CEO, phone +46 (0)31 746 56 00, +46 (0)708 369 403,
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Web site: www.artimplant.com
About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon®, a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements with two global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.
About Biomet
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. The Company's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
Source: Artimplant
|
